R R

What Is Nivolumab?

Nivolumab is a prescription immunotherapy medication that helps the immune system recognize and attack certain cancer cells. It is a programmed death receptor-1 (PD-1) blocking antibody marketed as Opdivo for intravenous administration. Nivolumab is approved for several cancers, including certain forms of melanoma, lung cancer, kidney cancer, and other malignancies. It can be administered alone or in combination with other cancer treatments, depending on the diagnosis and treatment setting.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Nivolumab?

Nivolumab is a prescription immunotherapy medication that helps the immune system recognize and attack certain cancer cells. It is a programmed death receptor-1 (PD-1) blocking antibody marketed as Opdivo for intravenous administration. Nivolumab is approved for several cancers, including certain forms of melanoma, lung cancer, kidney cancer, and other malignancies. It can be administered alone or in combination with other cancer treatments, depending on the diagnosis and treatment setting.

read more about nivolumab ...

Copy this HTML:

Copy HTML Copied!

How Does Nivolumab Work?

Nivolumab is a monoclonal antibody that binds to the PD-1 receptor on immune cells. Some cancer cells exploit the PD-1 pathway to reduce the ability of T cells to attack them. By blocking interactions between PD-1 and its ligands, nivolumab helps restore antitumor immune activity. This mechanism differs from traditional chemotherapy, which directly targets rapidly dividing cells. Increased immune activity can also cause inflammation in healthy organs and tissues.

What Types of Cancer Does Nivolumab Treat?

Nivolumab is approved for selected patients with melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer with specific molecular features, hepatocellular carcinoma, esophageal cancer, gastric and gastroesophageal junction cancers, and certain other malignancies. Approved uses depend on disease stage, previous treatment, biomarkers, and combination regimens. An oncologist determines eligibility according to the current prescribing information and individual cancer characteristics.

How Is Nivolumab Administered?

Intravenous nivolumab is administered by healthcare professionals through an infusion. Depending on the approved indication and regimen, adult dosing commonly involves 240 mg every two weeks or 480 mg every four weeks when given alone. Other dosing schedules apply when nivolumab is combined with ipilimumab or chemotherapy, and pediatric dosing can depend on body weight. Treatment duration varies by cancer type, response, and adverse effects. Patients are monitored for immune-related complications throughout treatment and after discontinuation.

What Are the Side Effects and Warnings of Nivolumab?

Common side effects include fatigue, rash, itching, diarrhea, and musculoskeletal discomfort. Serious immune-mediated complications can affect the lungs, intestines, liver, kidneys, skin, and hormone-producing glands. These reactions can be severe or life-threatening and may occur during treatment or after it ends. Nivolumab can also cause infusion-related reactions and harm an unborn baby. New breathing difficulties, persistent diarrhea, jaundice, unusual weakness, or vision changes require prompt medical assessment.

Common Questions About Nivolumab

Is nivolumab the same as Opdivo?

Yes. Opdivo is the brand name for intravenous nivolumab. Other nivolumab-containing products or formulations can have different administration requirements.

Is nivolumab chemotherapy?

No. Nivolumab is an immune checkpoint inhibitor that helps the immune system attack certain cancer cells. It can be combined with chemotherapy in specific treatment regimens.

How often is nivolumab administered?

Dosing depends on the cancer and treatment regimen. Common single-agent adult schedules include intravenous infusions every two or four weeks.

Can nivolumab cause eye problems?

Yes. Immune-related reactions can occasionally cause eye inflammation, including uveitis. New eye pain, redness, light sensitivity, or vision changes should be evaluated promptly.

References

DailyMed - OPDIVO (nivolumab) injection. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394. Date Accessed October 19, 2026.

Nivolumab. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548206/. Date Accessed October 19, 2026.

Nivolumab. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Nivolumab. Date Accessed October 19, 2026.

Nivolumab (OPDIVO). National Cancer Institute. https://dctd.cancer.gov/drug-discovery-development/reagents-materials/formulary/about/agents/nivolumab. Date Accessed October 19, 2026.

Nivolumab Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a614056.html. Date Accessed October 19, 2026.